Drugs / CNTO 2476
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00458575 | Apr 2007 → Aug 2013 | retinitis pigmentosa | Centocor, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01226628 | Oct 2010 → Mar 2015 | age-related macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02895815 | Apr 2018 → Feb 2021 | age-related macular degeneration | Janssen Pharmaceutical K.K. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02659098 | Dec 2015 → Jun 2019 | age-related macular degeneration, diffuse secondary choroid atrophy | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTO 2476 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01226628 ↗ |
| Modality | Cell therapy | “a single dose of viable cells” NCT00458575 ↗ |
| Route | Other | “injected subretinally” NCT00458575 ↗ |